Zentalis Pharmaceuticals Inc. - notizie pubblicate 214 - letture 3.648
ZENTALIS PHARMACEUTICALS INC.
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
New york and san diego, nov. 01, 2022 (globe newswire) -- zentalis™ pharmaceuticals, inc. (nasdaq: zntl), a clinical-stage biopharmaceutical company focused on discovering and de ...
ZENTALIS PHARMACEUTICALS INC.
Amendment to Annual Report - Form 10-K/A
Zntl-20211231 united states securities and exchange commission washington, d.c. 20549 form 10-k/a (amendment no. 1) (mark one) ☒ annual report pursuant to section 13 or 15(d) of ...
ZENTALIS PHARMACEUTICALS INC.
Zentalis Pharmaceuticals Announces First ZN-c3 Clinical Development Collaboration with Pfizer
Companies will collaborate on phase 1/2 dose escalation study of zn-c3, a selective wee1 inhibitor, in combination with encorafenib and cetuximab in patients with braf v600e-mutate ...
ZENTALIS PHARMACEUTICALS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
ZENTALIS PHARMACEUTICALS INC.
Zentalis Pharmaceuticals Appoints Dr. Mark Lackner as Chief Translational Officer, Head of Biomarker Strategy
New york and san diego, oct. 17, 2022 (globe newswire) -- zentalis™ pharmaceuticals, inc. (nasdaq: zntl), a clinical-stage biopharmaceutical company focused on discovering and de ...
ZENTALIS PHARMACEUTICALS INC.
Zentalis Pharmaceuticals Appoints Dr. Carrie Brownstein as Chief Medical Officer
New york and san diego, sept. 19, 2022 (globe newswire) -- zentalis™ pharmaceuticals, inc. (nasdaq: zntl), a clinical-stage biopharmaceutical company focused on discovering and d ...
ZENTALIS PHARMACEUTICALS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
ZENTALIS PHARMACEUTICALS INC.
Management Change - Form 8-K
Zntl-20220909 united states securities and exchange commission washington, d.c. 20549 -------------- form 8-k -------------- current report pursuant to section 13 or 15(d) of the s ...
ZENTALIS PHARMACEUTICALS INC.
Initial Statement of Beneficial Ownership - Form 3
Ownership submission form 3 united states securities and exchange commission washington, d.c. 20549initial statement of beneficial ownership of securities filed pursuant to section ...
ZENTALIS PHARMACEUTICALS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
ZENTALIS PHARMACEUTICALS INC.
Zentalis Pharmaceuticals Appoints Dr. Jan Skvarka to its Board of Directors
New york and san diego, sept. 12, 2022 (globe newswire) -- zentalis™ pharmaceuticals, inc. (nasdaq: zntl), a clinical-stage biopharmaceutical company focused on discovering and d ...
ZENTALIS PHARMACEUTICALS INC.
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Zentalis pharmaceuticals announces inducement grant under nasdaq listing rule 5635(c)(4) sep 1, 2022 at 5:00 pm edt pdf version new york and san diego, sept. 01, 2022 (globe newswi ...
ZENTALIS PHARMACEUTICALS INC.
Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences
Zentalis pharmaceuticals to participate in two upcoming investor conferences aug 31, 2022 at 7:00 am edt pdf version new york and san diego, aug. 31, 2022 (globe newswire) -- zenta ...
ZENTALIS PHARMACEUTICALS INC.
Corporate Presentation – June 2022
C o r p o r at e p r e s e n tat i o n j u n e 2 0 2 2 forward-looking statements and disclaimer zentalis pharmaceuticals, inc. ("we," "us," "our," &q ...
ZENTALIS PHARMACEUTICALS INC.
Statement of Changes in Beneficial Ownership (Form 4)
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
Per i consulenti finanziari
Abbiamo ricevuto 2.400 richieste di consulenza, pubblica il tuo profilo premium
per ricevere contatti e acquisire nuovi clienti